Moderna Sticks With Its Forecast Covid-19 Vaccine Sales; Stock Drops – The Wall Street Journal

Moderna shares were still down more than 6% in midday trading, making them the worst performers in the S&P 500.

The company said Monday it remains comfortable with its prediction of $6 billion to $8 billion in Covid-19 vaccine sales for 2023. Heres why:

See more here:

Moderna Sticks With Its Forecast Covid-19 Vaccine Sales; Stock Drops - The Wall Street Journal

Related Posts
Tags: